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Abstract
Background: While the etiology of depression is not clearly understood at the present time, this mental disorder is thought
be a complex and multifactorial trait with important genetic and environmental contributing factors.
Methodology/Principal Findings: The role of the endocannabinoid (eCB) system in depressive behavior was examined in
Wistar Kyoto (WKY) rat strain, a genetic model of depression. Our findings revealed selective abnormalities in the eCB
system in the brains of WKY rats compared to Wistar (WIS) rats. Immunoblot analysis indicated significantly higher levels of
fatty acid amide hydrolase (FAAH) in frontal cortex and hippocampus of WKY rats with no alteration in the level of N-
arachidonyl phosphatidyl ethanolamine specific phospholipase-D (NAPE-PLD). Significantly higher levels of CB1 receptor-
mediated G-protein coupling and lower levels of anandamide (AEA) were found in frontal cortex and hippocampus of WKY
rats. While the levels of brain derived neurotropic factor (BDNF) were significantly lower in frontal cortex and hippocampus
of WKY rats compared to WIS rats, pharmacological inhibition of FAAH elevated BDNF levels in WKY rats. Inhibition of FAAH
enzyme also significantly increased sucrose consumption and decreased immobility in the forced swim test in WKY rats.
Conclusions/Significance: These findings suggest a critical role for the eCB system and BDNF in the genetic predisposition
to depressive-like behavior in WKY rats and point to the potential therapeutic utility of eCB enhancing agents in depressive
disorder.
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Introduction
Major depressive disorder (MDD) is characterized by a signif-
icant impairment in mood and motivation [1], and exhibits
a chronic, relapsing course and is associated with high morbidity
and mortality worldwide. Depression is the leading cause of
disability and the 4th leading contributor to the global burden of
disease in 2000 [2]. In the United States alone, more than 30,000
people commit suicide each year; majority of which are associated
with depression [2,3]. Although the etiology of this disorder is not
clearly understood, clinical observations suggest a significant role
for the monoamine neurotransmitter systems [4]. However,
currently used antidepressants, which alter the monoamine
systems, appear to be therapeutically inadequate in many patients.
Thus, further studies are needed to understand the pathophysi-
ological basis of depression and for developing more effective
therapeutic agents.
Recent studies have implicated the eCB system in neuropsy-
chiatric disorders including depression and suicide [5]. A potential
role for the brain eCB system in the pathophysiology of MDD was
initially demonstrated in a post-mortem study that showed
upregulation of CB1 receptor in dorsolateral prefrontal cortex
(DLPFC) of depressed suicide victims [6]. Since then, a number of
studies have examined the role of the eCB system in the
neurobiology of depression; however, the findings have been
contradictory in that antidepressant-like properties have been
reported for both CB1 receptor agonist as well as the antagonist
[7–14]. Given that depressive disorder is a complex and
multifactorial trait with important genetic and environmental
contributing factors, several genetic animal models have been
developed in order to identify factors that underlie predisposition
to depression and to develop pharmacotherapy [15,16]. Previous
studies have established Wistar Kyoto (WKY) rat as an important
animal model of depressive disorder [15,17–21]. In the present
study, we investigated whether dysfunction in the brain eCB
system is associated with depressive-like behavior in WKY rat. To
further understand the molecular mechanisms downstream of the
eCB system, the effect of FAAH inhibition on BDNF was also
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investigated as it has been shown to be critically involved in the
etiology of major depression and in antidepressant effects [22].
Materials and Methods
Animals
WKY and WIS rats (10–12 week old male rats) used for this
study were procured from Charles River laboratories and bred at
the Animal Facility of the Nathan Kline Institute (NKI). Rats were
housed at 2361uC for 12 h light/dark cycle in a group of two rats
and habituated to environment and handling for a week prior to
the experiments. Animal care and handling procedures were done
in accordance with the Institutional and NIH guidelines. The
animal care protocol was approved by the Institutional Animal
Care and Use Committee of the NKI (# AP2009-297). For basal
comparison, WKY rats and the control WIS rats were euthanized
under anesthesia (chlorate hydrate 400 mg/kg, i.p.) and brain
regions (frontal cortex and hippocampus) were dissected on ice.
Brain regions were used for the analysis of AEA, FAAH, CB1
receptor, CB1 receptor-mediated G-protein activation and BDNF.
The effects of pharmacological inhibition of FAAH (URB597,
0.3 mg/kg body wt, i.p.) for 7 days on depressive-like phenotype,
AEA, CB1 receptor-mediated G-protein activation and BDNF
levels were also examined in WKY rats compared to vehicle
treated WKY rats.
AEA Assay
Levels of eCB, AEA, were determined using liquid chromatog-
raphy mass spectroscopy (LC-MS) following the isotopic dilution
procedure described previously [23]. Briefly, tissue was homoge-
nized in 4 ml of chloroform-methanol-tris buffer (2:1:1, pH 7.4)
containing 0.25 mM PMSF, 0.2% BHT, 50 ng of AEA-d8. The
homogenate was centrifuged at 1,000 g and the organic layer was
taken to dryness with nitrogen. The residue was dissolved in ethyl
acetate (0.3 ml) and centrifuged. The supernatant was dried and
the residue was redissolved in alcohol (30 ml) and transferred to
a vial for the measurement of AEA by LC-MS. The standard
curve was fitted with a quadratic equation with the curve
encompassing a range of 1–50 ng and was processed similarly
with quality controls with each batch of samples.
Immunoblot Analysis
An aliquot of tissue homogenate (30 mg protein) was electro-
phoresed using 12% polyacrylamide gel and transferred to
nitrocellulose membrane. Membrane was treated with blocking
buffer (TTBS, [10 mM Tris, 0.9% NaCl; 1% Tween 20 contain-
ing 5% milk powder] of pH 7.4) for 1 hr at room temperature.
Membrane was then incubated with antibodies for FAAH, NAPE-
PLD and CB1 receptor, (Abnova, Taipei City, Taiwan) overnight
at 4uC. The blot was washed with TTBS and then incubated with
HRP conjugated anti-IgG for 1 hr at room temperature. After
washing the blot with TTBS, the immunoreactive band was
visualized using ECL reagent (GE Health Care, Piscataway, NJ).
The blot was reprobed with tubulin antibody to ensure equal
protein loading.
Real-time Quantitative PCR (qPCR) Studies with FAAH
Total RNA was extracted using Ambion AqueousRNA-4PCR
kit (Life Technologies, Carlsbad, CA). RNA quality and concen-
tration were measured using a ND-1000 instrument (Thermo
Fisher Scientific, USA) and a 1% agarose gel. For cDNA synthesis,
1 mg RNA from each sample was reverse transcribed to cDNA
using High Capacity RNA-to-cDNA Kit (Life Technologies,
Carlsbad, CA). qPCR was performed using Gene Expression
Assays FAAH (Rn00577086_m1) and ActB (Rn00667869_m1) on
a ABI Prism 7900 HT instrument (Life Technologies, Carlsbad,
CA). Reactions were set on 384-well plates (BioRad, Hercules,
CA) in a volume of 20 ml containing 100 ng of cDNA template,
1 ml Gene Expression Assay and 10 ml TaqMan Gene Expression
Master Mix (Life Technologies, Carlsbad, CA). A no-template
control (NTC) was performed for each primer set used. The
thermal profile was as follows: 2 minutes at 95uC, followed by 45
cycles of amplification where each cycle comprised of 12 seconds
at 95uC and 60 seconds at 60uC. Each sample was assayed in
triplicate. The qPCR data was analyzed using SDS2.4 software
(Life Technologies, Carlsbad, CA).
Measurement of FAAH Activity
The FAAH activity was measured as described previously
[7,24]. Briefly, tissue homogenate (25–50 mg of total protein) was
incubated with 30 mM AEA (ethanolamine1-3H) (10–20 Ci/
mmol) in a solution containing 0.1 M Tris-HCl (pH 8.0), 0.1%
BSA, for 30 min at 37uC. After incubation, samples were
extracted by organic solvent (chloroform and methanol; 1:1) and
subjected to liquid scintillation counting.
Agonist-stimulated [35S]GTPcS Binding Assay
The [35S]GTPcS binding assay was performed in crude
synaptic membrane isolated from frontal cortex and hippocam-
pus as described previously [24]. Briefly, all ligands were diluted
in assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 100 mM
NaCl, 1 mM EDTA) containing 0.1 mg/ml fatty acid-free BSA.
The assay mixture was incubated in silicone-treated test tubes
for 1 hr at 30uC. Reaction was terminated by adding 2 ml of
ice-cold Tris-HCl buffer. Membranes were rapidly filtered
through GF/B filters using a Brandel 48-position cell harvester
and were washed with ice-cold wash buffer (50 mM Tris-HCl).
The filters were transferred to scintillation vials containing 5 ml
of scintillation cocktail and the radioactivity was measured using
a liquid scintillation counter at an efficiency of 95% for 35S.
Non-specific binding was determined by addition of 100 mM
unlabeled GTPcS. The CB1 antagonist (SR141716A) was used
to study the specificity of CB1 agonist [CP-55,940; 1 mM]
stimulated [35S]GTPcS binding.
Forced-swim Test, Sucrose Intake and Spontaneous
Motor Activity
Antidepressant-like property of URB597 was evaluated using
the forced-swim test (FST) as it is a sensitive and reliable method
with high predictive validity [7,25]. The dose and duration of
treatment were selected based on the literature [7]. WKY rats
were treated with FAAH inhibitor, URB597 (0.3 mg/kg body wt,
i.p.) once daily in the morning (10 AM) for 7 days. The control
WKY rats received vehicle (saline containing 1% DMSO and 1%
Tween 20). After 3 hr following the administration of last dose of
URB597, rats were tested for FST and sucrose consumption [7].
During the 30 min swim test, the rat behavior was videotaped.
The main behaviors, immobility (no or minimum movement),
swimming and climbing were assessed. A potential drug-induced
change in the spontaneous locomotor activity in an open field
(Columbus Instruments, Columbus, OH) was also measured for
30 min. For the sucrose consumption test, rats were housed in
individual cages and offered access to preweighed bottles contain-
ing tap water and 1% sucrose 3 hr after the last injections of
URB597. The amount of water and sucrose consumption was
measured for 2 hr.
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BDNF Levels
Basal levels of BDNF were measured using Sandwich Elisa Kit
(Millipore, Temecula, CA) in frontal cortex and hippocampus of
WKY and WIS rats. The effect of URB597 (0.3 mg/kg body wt,
i.p.) treatment for 7 days on BDNF levels were also measured in
WKY rats compared to vehicle treated WKY rats after 3 hr
following the last dose of URB597.
Statistical Analysis
The statistical analyses were performed using independent
student ‘‘t’’ test (GraphPad Software, San Diego, CA). All the
statistical analyses were run on the raw data. The data on innate
differences in the eCB system and BDNF between the groups
(WKY and WIS rats) were analyzed using unpaired ‘‘t’’ test.
Paired ‘‘t’’ tests were applied for the analysis of the data on the
effect of pharmacological treatment on depressive-like behavior,
spontaneous activity, sucrose consumption and BDNF levels in
WKY rats compared to vehicle treated WKY rats. The qPCR
data on FAAH, normalized to b-Actin (endogenous reference) was
given by 22DDCt. Statistical differences were considered to be
significant at p,0.05. The values (mean6SEM) are presented as
percentage over the control groups or otherwise stated.
Results
Basal Differences in the Components of eCB System in
the Brains of WIS and WKY Rats
Basal levels of eCB, AEA were found to be significantly lower in
hippocampus of WKY rats compared to WIS rats (31%, p,0.01,
n = 526; Fig. 1A). Basal level of FAAH enzyme was significantly
higher in frontal cortex (40%, p,0.05) and hippocampus (40%,
p,0.05) of WKY rats compared to WIS rats (n = 6 in each group;
Fig. 1B). A representative immunoblot is provided in the upper
panel (Fig. 1B). The qPCR analysis also confirmed higher levels of
Figure 1. Basal differences in AEA and FAAH levels in the brain of WKY rats. The level of eCB, AEA was found to be significantly lower in
hippocampus of WKY rats compared to WIS rats (31%, p,0.01; A). Conversely, the level of FAAH enzyme was significantly higher in frontal cortex
(40%, p,0.05) and hippocampus (40%, p,0.05; B) of WKY rats. A representative immunoblot for hippocampus is provided in the upper panel (B). The
qPCR analysis also indicated higher levels of mFAAH in hippocampus of WKY rats (24%, p,0.05; C). The qPCR data on FAAH, normalized to b-Actin
(internal standard) is presented as the fold change relative to the control value of 1.0. The FAAH activity was slightly higher in frontal cortex (15%,
p,0.05) and hippocampus (17%, p,0.05) of WKY rats compared to WIS rats (D). Hippo; Hippocampus.
doi:10.1371/journal.pone.0036743.g001
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mFAAH in hippocampus of WKY rats than WIS rats (24%,
p,0.05; Fig. 1C; n= 4). A subtle but statistically significant higher
activity of FAAH enzyme was observed in frontal cortex (15%,
p,0.05) and hippocampus (17%, p,0.05; n= 628; Fig. 1D) of
WKY rats than WIS rats. There were no significant differences in
the levels of NAPE-PLD enzyme in frontal cortex and hippocam-
pus of WKY compared to WIS rats (Fig. 2). A representative
immunoblot is provided in the upper panel (Fig. 2). The CB1
receptor-stimulated [35S]GTPcS binding was significantly higher
in frontal cortex (24%, p,0.05) and hippocampus (44%, p,0.01)
of WKY rats compared to WIS rats (n = 628; Fig. 3A). Western
blot analysis revealed significantly higher levels of CB1 receptors in
hippocampus (45%, p,0.05), however, they were slightly higher
in frontal cortex of WKY rats (18%, n= 628; Fig. 3B).
Effect of FAAH Inhibition on FST and Sucrose Intake
Pharmacological inhibition of FAAH with URB597 (0.3 mg/kg,
i.p. for 7 days) elicited a significant decrease in total time spent in
immobility (50%, p,0.01; Fig. 4A) and increased sucrose intake
(48%, p,0.05; Fig. 4B) without affecting the spontaneous
locomotor activity in the open field in WKY rats compared to
vehicle treated WKY rats (n = 528; Fig. 4C).
Effect of FAAH Inhibition on AEA, CB1 Receptor Function
and BDNF
Basal levels of BDNF were found to be significantly lower in
frontal cortex (27%) and hippocampus (26%) of WKY rats
compared to WIS rats (p,0.05; n = 426; Fig. 5A). Subchronic
URB597 treatment (0.3 mg/kg, i.p. for 7 days) markedly elevated
BDNF levels in frontal cortex (64%) and hippocampus (45%) of
WKY rats compared to vehicle treated WKY rats (p,0.05;
n = 426; Fig. 5B). This treatment was accompanied by significant
increase in AEA levels in frontal cortex (31%, p,0.01; Fig. 5C)
and hippocampus (42%, p,0.001; Fig. 5C), and decrease in CB1
receptor-mediated G-protein activation (21%, p,0.05; Fig. 5D) in
frontal cortex of WKY rats compared to vehicle treated WKY rats
(n = 426).
Discussion
Previous behavioral and biochemical studies have established
the WKY rat as an important genetic animal model of depressive
behavior [15–21]. To our knowledge, the present study is the first
to explore the role of the eCB system in this model. The findings
revealed a higher CB1 receptor-mediated G-protein activation in
frontal cortex and hippocampus of WKY rats compared to the
control strain, WIS rats. This is in agreement with our previous
study that reported higher levels of CB1 receptor-mediated G-
protein coupling in DLPFC of depressed patients [6]. While CB1
receptors were not found to be significantly higher in frontal cortex
of WKY rats, the potential changes in G-protein levels and brain
regions of interest (DLPFC versus frontal cortex) might be
contributing factors for this discrepancy. Alterations in the
metabolic enzymes of eCBs due to stress or any other insults
could alter eCB tone leading to adaptive changes in CB1 receptor
signaling. In animal studies, exposure to stress is shown to reduce
eCB levels and upregulate mRNA of CB1 receptor [26,27].
Notably, we found significantly lower AEA levels in hippocampus
of WKY rats compared to WIS rats. Therefore, sensitization of
CB1 receptor might be a compensatory adaptation in response to
Figure 2. Basal levels of NAPE-PLD in the brain of WKY rats.
There were no significant differences in the levels of NAPE-PLD enzyme
in frontal cortex and hippocampus of WKY rats compared to WIS rats
(A). A representative immunoblot for hippocampus is provided in the
upper panel (B). Hippo; Hippocampus.
doi:10.1371/journal.pone.0036743.g002
Figure 3. Basal differences in CB1 receptor in the brain of WKY
rats. The CB1 receptor agonist-stimulated [35S]GTPcS binding was
significantly higher in frontal cortex (24%, p,0.05) and hippocampus
(44%, p,0.01) of WKY rats compared to WIS rats (A). Data is presented
as percentage of stimulation over basal binding. Western blot analysis
revealed significantly higher levels of CB1 receptors in hippocampus
(45%, p,0.05), while they were found to be slightly higher in frontal
cortex of WKY rats (18%, B). Hippo; Hippocampus.
doi:10.1371/journal.pone.0036743.g003
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Figure 4. Effect of FAAH inhibition on depressive-like behavior in WKY rats. Treatment with URB597 (0.3 mg/kg, i.p. for 7 days) elicited
a significant decrease in total time spent in immobility (50%, p,0.01; A) and a marked increase in sucrose intake (48%, p,0.05; B) without any effect
on the spontaneous locomotor activity in the open field (C) in WKY rats compared to vehicle treated WKY rats.
doi:10.1371/journal.pone.0036743.g004
Figure 5. Effect of FAAH inhibition on BDNF, AEA and CB1 function in the brain of WKY rats. Basal BDNF levels were found to be
significantly lower in frontal cortex (27%) and hippocampus (26%) of WKY compared to WIS rats (p,0.05; A). Subchronic treatment with URB597
(0.3 mg/kg, i.p. for 7 days) significantly elevated BDNF levels in frontal cortex (64%) and hippocampus (45%) of WKY rats compared to vehicle treated
WKY rats (p,0.05; B). Inhibition of FAAH was accompanied by significant increase in AEA levels in frontal cortex (31%, p,0.01; C) and hippocampus
(42%, p,0.001; C), and a subsequent decrease in CB1 receptor-mediated G-protein activation in frontal cortex of WKY rats (21%, p,0.05; D). Hippo;
Hippocampus.
doi:10.1371/journal.pone.0036743.g005
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diminished eCB tone. The reduction in AEA levels appears to be
mainly due to higher activity of FAAH enzyme in WKY rats
compared to WIS rats. To understand a relevance of upregulation
of CB1 receptors/G-protein activation to depressive behavior, we
examined CB1 receptor-mediated G-protein coupling following
drug treatment. Subchronic FAAH inhibition led to a subtle but
statistically significant reduction in CB1 receptor-mediated G-
protein activation in frontal cortex of WKY rats. This de-
sensitization is likely due to a neuroadaptation to persistent
elevation of AEA and activation of CB1 receptors. It remains to be
determined if chronic (or higher dose) of URB597 treatment is
required to attenuate hippocampal CB1 receptors in WKY rats.
The observed effects are likely mediated through CB1 receptors,
since several previous studies have demonstrated that URB597
treatment elevates AEA and exerts its effect through CB1
receptors in other rodent models [7,28–32].
We further investigated whether elevation of AEA through
inhibition of FAAH activity has an antidepressant-like property in
WKY rats. The rationale for selecting FAAH inhibitor over CB1
receptor agonist is that (1) FAAH level and activity was found to be
higher in brain of WKY rats in the present study and (2) direct
modifications of CB1 receptor signaling using CB1 receptor
agonists have shown to exert variable side effects [27]. Our results
demonstrate that subchronic inhibition of FAAH with URB597
elicits a significant decrease in total time spent in immobility
without any effect on spontaneous locomotor activity in the open
field in WKY rats. Inhibition of FAAH by URB597 is reported to
enhance the accumulation of AEA after 2 hrs of treatment and
produces an antidepressant-like effect in a rat model of subchronic
mild stress [7,10]. The cannabinoids have been shown to elicit
antidepressant-like behavior, probably through the activation of
serotonergic neurons in medial prefrontal cortex [9]. It remains to
be seen if antidepressant-like property of URB597 in WKY rats is
linked to an increase in brain serotonergic system. Furthermore,
polymorphism in FAAH gene is shown to be associated with
bipolar disorder and major depression [33]. However, it is yet to
be determined if such a polymorphism is related to an increase in
the expression and/or activity of FAAH.
Our study further demonstrates that pharmacological inhibition
of FAAH enzyme significantly increases the sucrose consumption
in WKY rats. Increase in sucrose intake following FAAH
inhibition appears to be related to a decrease in hedonic response
leading to increased sensitivity to reward. It is interesting to note
that enhancement of the CB1 receptor-mediated signaling in
hippocampus elicits an antidepressant-like effect in rodents
[34,35], suggesting an association of reduction in the eCB
signaling with stress and depressive behavior. Conversely, there
are a number of studies where both agonist and antagonist of CB1
receptors have been shown to act as antidepressants [5–14,27].
These discrepancies may be due to differences in animal species,
strains used, behavioral paradigms (e.g. FST vs CMS or learned
despair etc), drugs or dosages used in various studies. In addition,
interspecies or interstrain differences in brain regional distribution
of the eCB system may also influence the behavioral outcome.
Recent imaging studies in humans have provided information
about the neuroanatomical correlates of mood disorders. The
biochemical and morphological changes in prefrontal cortex and
hippocampus are reported in patients with mood disorders. The
hippocampus is an important brain region of the limbic stress
pathway and a major feedback site for glucocorticoids in response
to stress [36–42]. Stress has also been shown to adversely affect
cortical and hippocampal function by deregulating expression of
neurotrophic factors that promote neuronal plasticity. For in-
stance, an etiological link between the development of depression
and BDNF has been suggested [22]. Exposure to stress is shown to
decrease the expression of BDNF while antidepressant treatment
and electroconvulsive therapy increase the expression of BDNF
[43–52]. Our findings have revealed for the first time the existence
of lower levels of BDNF in frontal cortex and hippocampus of
WKY rats compared to WIS rats. Furthermore, BDNF appears to
be under the regulation of AEA-mediated signaling since FAAH
inhibition elevated its level in WKY rats. Consistent with these
observations, previous studies have shown that CB1 knockout mice
exhibit an augmented response to stress (increased despair
behavior and corticosterone) with decreased BDNF levels in
hippocampus [53]. Notably, local administration of BDNF in
hippocampus reversed the increased despair behavior of CB1
knockout mice. The cannabinoids appear to elicit antidepressant-
like effects through promotion of hippocampal neurogenesis [54].
It remains to be seen if eCB-mediated BDNF function promotes
neuronal plasticity leading to attenuation of depressive-like
behavior in WKY rats. Although the role of BDNF in depressive
behavior is yet to be clearly understood, a potential role of genetic
variation in BDNF and antidepressant treatment outcome in
depression has been reported [43,55].
The cAMP-CREB pathway is a target of monoamines and
several other neuromodulatory systems, and may play a pivotal
role in neuronal plasticity associated with stress and depression
[56,57]. The CB1 receptor is among the most abundant
neuromodulatory GPCRs in brain, and is coupled to adenylyl
cyclase and ERK via Gi/o-protein. It is possible that alterations in
the CB1 receptor-mediated G-protein activation could change
cAMP content, subsequently affecting the activity of PKA-CREB
pathway and gene regulation. In addition, modulation of the
hypothalamus-pituitary axis by the eCB system and antidepres-
sant-like properties of the cannabinoid drugs further support
involvement of this system in the pathophysiology of depression
[5]. Taken together, our study demonstrates the selective
abnormalities in the eCB system of WKY rats and further suggests
the potential therapeutic utility of AEA enhancing agents in the
treatment of depressive behavior. Consistent with previous studies
that reported a potential contribution of gene variants in CB1
receptor and FAAH enzyme to the susceptibility of depressive
behavior [58,59], the present findings further corroborate a critical
role of the eCB system in genetic model of depressive behavior.
Future studies investigating other components of the eCB system
in additional limbic brain regions such as striatum and amygdala
will further our understanding of the pathophysiology of de-
pression. It also remains to be examined whether AEA enhancing
agents will provide a beneficial effect in the treatment-resistant
depressive disorder.
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